20 Sep 2025 | 5 Mins Read
Novartis prepared for Trump tariffs with stockpiles, CEO claims
Flipitmoney
Novartis CEO Vas Narasimhan stated the company has increased its U.S. stockpiles to last until mid-2026. They plan to manufacture key products locally with $23 billion in investments. Novartis aims to minimize tariffs by shifting production, estimating significant progress in two years. A 250% tariff following the Section 232 investigation is uncertain, but Novartis is working on all scenarios.